



NOVAVAX

Creating Tomorrow's Vaccines

Rahul Singhvi, President & CEO

April 17, 2008


Safe Harbor Statement

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding clinical development, product sales, operating expenses, and anticipated milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including Novavax's ability to progress any product candidates in pre-clinical or clinical trials; the scope, rate and progress of its pre-clinical trials and other research and development activities; the scope, rate and progress of any clinical trials we commence; clinical trial results; risks relating to the early stage of Novavax's product candidates under development; even if the data from pre-clinical or clinical trials is positive, the product may not prove safe and efficacious; Novavax's pilot plant facility is subject to extensive validation and FDA inspections, which may result in delays and increased costs; the failure by Novavax to secure and maintain relationships with collaborators; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of Novavax's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at <http://www.sec.gov>. These forward-looking statements speak only as of the date of this presentation, and Novavax assumes no duty to update forward-looking statements.


Creating Tomorrow's Vaccines

- Robust vaccine pipeline addressing major markets
- Proprietary, proven VLP technology platform
- Applicable to multiple disease targets
- Near-term clinical value drivers
- New, efficient manufacturing solution and capacity
- Multiple approaches to commercialization
- Strong financial position and flexibility


Strong Pipeline Targeting Major Markets



Novavax Proprietary VLP Technology



e.g. Gardasil®
(HPV vaccine)



Patent protection for VLP matrix platforms


e.g. Influenza vaccine

VLP Technology Advantage

- Proven in first-generation HPV and HBV VLP vaccines
- Novavax' VLP nanoparticles incorporate immunologically important recombinant proteins and lipid structures
- Designed to induce robust and broad immune responses similar to natural infection
- Potential to address wide range of disease targets
- Simpler, safer, more efficient and scalable manufacturing

Pandemic Influenza Vaccine: Positive Interim Phase I/IIa Results

- Proof of concept for VLP technology
- Safe, well-tolerated and immunogenic at two doses
 - 3 arm study: 15 mcg, 45 mcg, placebo
 - 70 subjects (healthy adults), 18-40 years
- Significant rise in antibody titers vs. baseline
 - At 45 mcg dose (n=35)
 - » 63% of subjects - 4x rise of neutralizing antibody titres
 - » 47% of subjects - 8x rise
- Dose-ranging Phase II study ongoing
 - 15ug, 45ug, 90ug
 - Interim topline results expected 3Q08




Seasonal Influenza Opportunity

- Potential market > \$3 billion globally
- Significant patient population each year
 - 30 million infected, >36,000 deaths
- U.S. continues to expand vaccination recommendations
 - New pediatric recommendations
- Current vaccines deficient in the most exposed populations
 - Pediatric, elderly

Seasonal Influenza Vaccine Program Progress

- Probability of success enhanced by interim H5N1 data
- Parallel development strategy
 - Develop recombinant product w/o adjuvant using defined regulatory pathway
 - Study efficacy in older adults for superiority vs. standard care
- All 2008 CDC vaccine strains cloned in six weeks
 - Novavax VLPs can be produced in $\sim\frac{1}{2}$ the time of other vaccines
- Near-term development timelines
 - Commence and report topline data from Phase II trial 3Q 2008




Influenza: The Novavax Advantage

Well-Suited to Address Seasonal and Pandemic Illness

- Technology
 - Proprietary Novavax VLP nanoparticles
 - » Increased efficacy vs. egg or mammalian cell line vaccines
 - » Greater immunogenicity in pediatric/elderly patients
 - » Faster, lower-cost manufacturing
- Ability
 - Proven and distinguished leadership
 - » 100+ years of relevant vaccine development
- Agility
 - Novavax VLPs can be produced in ~½ the time of other vaccines
 - » All 2008 CDC vaccine strains cloned in six weeks
- Presence
 - In-border manufacturing increases worldwide presence
 - Ensures quick scale-up production vs. 4+ years for egg-based facility

Varicella Zoster Virus (VZV) Vaccine Opportunity

- Potential market > \$1 billion annually in the U.S.
- > 1 million cases of herpes zoster (shingles) in the U.S. annually
 - ~65% of infected patients contract post-herpetic neuralgia (PHN)
- Large market with only one vaccine supplier (live, frozen vaccine)
- Only one vaccine currently marketed
 - ~50% efficacy against shingles
 - ~39% efficacy against PHN



New, Efficient Manufacturing Solution



- Pre-sterilized, ready-to-use, disposable equipment



- Synergies of a single production platform for multiple vaccines

Novavax Manufacturing Advantage

<i>Traditional Approach</i>	<i>Novavax Manufacturing</i>
High CAPEX	Greatly reduced capital costs (~80%)
Low yield	Higher yields
Long time to commissioning/return on investment	Can cut commissioning time in half; faster return on investment
Centralized, large factories	Distributed manufacturing
Single product facility	Multiple product facility

Flexible Commercialization Strategy

- Partner with an organization/region
- Commercialize products directly (e.g., seasonal influenza)
- Provide in-border manufacturing solution with GE Healthcare
- Non-dilutive financing

Pandemic Influenza Vaccine Opportunity



*“This will almost certainly be the greatest health crisis experienced for almost a century.”**

**M. Chan, Director-General of the World Health Organization 6/13/07*

- Global budgets for pandemic preparedness > \$13 billion
- Market segments include:
 - Stockpiling
 - Capacity pre-purchase
 - Domestic supply through local infrastructure
- Insufficient worldwide vaccine capacity
 - Governments’ desire for more affordable in-border vaccine infrastructure


GE Collaboration: In-Border Manufacturing Solution

*Leverages NVAX VLP technology/GE development, marketing
Expertise*

- Cost-effective, turn-key resource
 - Process easily transferred
- Customizable, franchise-like approach
 - Allows each country to address local diseases
- Eliminates dependence on external suppliers
 - Relieves “closed border” concern of pandemic
 - Initially for pandemic preparedness, other indications to follow
 - Ensures quick scale-up production vs. 4+ years for egg-based facility

Commercialization Outline: Potential Arrangement

- NVAX contracts with Government “A”/partner to produce and sell vaccine at agreed upon price
- NVAX transfers know-how/license to local government/partner
- Vaccine produced by sub-contracted partner/CMO for local production
- GE supplies disposable technology
- Opportunity to supply other vaccine products



Strong Financial Position

NASDAQ: NVAX

Shares outstanding:	62.0 million
Current Market Capitalization (4/3/08):	\$162.3 million
Cash, Equiv. & Short Term (12/31/07):	\$46.5 million
2007 Burn:	\$27.1 million

Financing Options: Partnering; non-dilutive and equity

100+ Years of Vaccine Development Experience

- **John Lambert: Chairman of the Board**
30 years in vaccines, Former President Chiron Vaccines, Former President APMSD (Aventis/Merck joint venture)
- **Rahul Singhvi, ScD, MBA: President and CEO**
14 years in vaccines (Merck, Novavax)
- **Penny Heaton, MD: Chief Medical Officer and VP Development**
7 years with Merck Vaccines; rotavirus vaccine development leader
- **Gale Smith, PhD: VP Vaccine Research**
30+ years experience in biotech/vaccines; baculovirus system inventor
- **Jim Robinson: VP Technical & Quality Operations**
20+ years in process development and manufacturing with Sanofi Pasteur
- **Other Executive Committee Members**
 - Len Stigliano, CFO
 - Ray Hage, SVP, Commercial Operations
 - Tom Johnston, VP, Strategy

Key 2008 Milestones

- Top line data for Pandemic flu Phase II trial 3Q 2008
- Commence and report topline data for seasonal flu Phase II trial 3Q 2008
- Advance one additional discovery program into late preclinical testing 2H 2008
- Seek non-dilutive funding for Pandemic Flu program Ongoing
- Continue to enhance manufacturing yield 4Q 2008

Investment Highlights

- Robust vaccine pipeline addressing major markets
 - Pandemic and seasonal influenza, VZV, others
- Proprietary, proven technology platform
 - VLPs address broad range of diseases
- Near-term clinical value drivers
 - Topline data from pandemic Phase II trial expected 3Q08
 - Commence and report topline data from seasonal flu Phase II trial 3Q 2008
- New, efficient manufacturing solution and capacity
- Multiple approaches to commercialization
 - Including GE Healthcare collaboration
- Strong financial position and flexibility
- Seasoned, experienced management team



NOVAVAX

Creating Tomorrow's Vaccines

Rahul Singhvi, President & CEO

April 17, 2008